B Lymphocyte Populations in the Pulmonary Microenvironment of Patients Under Mechanical Ventilation With or Without VAP (Ventilator-Associated Pneumonia)

Condition(s) studied

Study summary

Diagnosis of VAP relies on a set of non-specific clinical, biological, and imaging criteria.

Understanding host-pathogen interactions and the mechanisms of deregulations leading to infection of pulmonary tissue appears essential.

The aim is to qualitatively describe the B lymphocyte populations present in the pulmonary microenvironment of patients admitted to intensive care and requiring invasive mechanical ventilation

Eligibility

Primary outcome measure(s)

• Qualitative description of B lymphocyte populations by flow cytometry analysis with specific antibodies — At the inclusion (T1), at diagnosis (T2 on the day of VAP diagnosis for patient who will develop it, on average 72 hours after the inclusion), at the end of the study (T3 on the day before extubation, on average 5 days after the inclusion)
  To qualitatively describe the B lymphocyte populations in the endotracheal aspirates of patients admitted to intensive care and requiring invasive mechanical ventilation. B lymphocyte subpopulations will be described using a flow cytometry method using antibodies targeting the following markers: CD93, CD62L, CD14, CXCR4, CD32, CD27, CD38, CD138, CD3, CD10, CD19, CD20, kappa light chains, lambda light chains.

Trial sites (1)

More University Hospital, Limoges trials in France

Other trials for the same condition